Objective: To analyze trends in prevalence, mortality, and disability-adjusted life years (DALYs) of childhood thalassemia from 1990 to 2021. Methods: Using the 2021 Global Burden of Disease (GBD) database, we conducted a cross-sectional study of children aged 0 - 14 years across 204 countries. We analyzed prevalence, mortality, and DALYs by region, country, age, sex, and Sociodemographic Index (SDI), calculating average annual percentage changes (EAPCs) to assess trends. Results: In 2021, there were 869,327 cases of childhood thalassemia globally. From 1990 to 2021, global prevalence decreased by 19.09%, and deaths declined from 12,018 to 5897. The mortality rate dropped from 0.69 to 0.29 per 100,000. High SDI regions had the lowest prevalence, mortality, and DALYs, all showing downward trends. Middle SDI regions had higher prevalence rates, while low and lower-middle SDI regions saw increases. Cambodia had the highest prevalence rate in 2021 (418 per 100,000), China had the highest number of cases (327,889), Pakistan had the highest DALYs (116987.40), and Guinea-Bissau had the highest DALYs rate (155.55 per 100,000). Conclusions: Childhood thalassemia remains a significant global health challenge. Despite declines in global prevalence, mortality, and DALYs, the burden remains high, especially in low SDI regions. Understanding the epidemiology of childhood thalassemia can aid in its prevention and control.
References
[1]
Shahmirzalou, P., Hamze, M.S. and Sadagheyani, H.E. (2024) A New Formula Based on Simple Blood Indices to Differentiate Beta Thalassemia Trait from Iron Deficiency Anemia. IranianJournalofPublicHealth, 53, 1192-1199. https://doi.org/10.18502/ijph.v53i5.15601
[2]
Saeidnia, M., Shadfar, F., Sharifi, S., Babashahi, M., Ghaderi, A. and Shokri, M. (2024) Skin Complications during Iron Chelation Therapy for Beta-Thalassemia: Overview and Treatment Approach. InternationalJournalofHematology, 120, 271-277. https://doi.org/10.1007/s12185-024-03825-w
[3]
Banjade, P. and Bhandari, J. (2020) A Child Lost to Follow up Carrying Beta Thalassemia Major: A Case Report. JournalofNepalMedicalAssociation, 58, 436-438. https://doi.org/10.31729/jnma.5129
[4]
Avraham, K., Benjamin, W., Elizabeth, Y., et al. (2023) Association and Risk Factors of Pediatric Pulmonary Hypertension with Obstructive Sleep Apnea: A National Study Utilizing the Kids’ Inpatient Database (KID). InternationalJournalofPediatricOtorhinolaryngology, 175, Article ID: 111750.
[5]
Lan, X., Ye, Z., Du, J., Liu, L., Tian, C., Huang, L., et al. (2024) Cross-Sectional Study on the Impact of Cardiac and Hepatic Iron Overload, as Measured by MRI T2*, on the Quality of Life in Children with Severe Beta-Thalassemia Major. Medicine, 103, e38817. https://doi.org/10.1097/md.0000000000038817
[6]
Babar, S. and Saboor, M. (2024) Erythroferrone in Focus: Emerging Perspectives in Iron Metabolism and Hematopathologies. BloodScience, 6, e00198. https://doi.org/10.1097/bs9.0000000000000198
[7]
GBD Diseases and Injuries Collaborators (2024) Global Incidence, Prevalence, Years Lived with Disability (YLDs), Disability-Adjusted Life-Years (DALYs), and Healthy Life Expectancy (HALE) for 371 Diseases and Injuries in 204 Countries and Territories and 811 Subnational Locations, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet, 403, 2133-2161.
[8]
GBD 2019 Diseases and Injuries Collaborators (2020) Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. The Lancet, 396, 1204-1222.
[9]
GBD 2013 Mortality and Causes of Death Collaborators (2015) Global, Regional, and National Age-Sex Specific All-Cause and Cause-Specific Mortality for 240 Causes of Death, 1990-2013: A Systematic Analysis for the Global Burden of Disease Study 2013. The Lancet, 385, 117-171.
[10]
Ding, Q., Liu, S., Yao, Y., Liu, H., Cai, T. and Han, L. (2022) Global, Regional, and National Burden of Ischemic Stroke, 1990-2019. Neurology, 98, e279-e290. https://doi.org/10.1212/wnl.0000000000013115
[11]
Glenthøj, A., van Beers, E.J., van Wijk, R., Rab, M.A.E., Groot, E., Vejlstrup, N., et al. (2024) Designing a Single-Arm Phase 2 Clinical Trial of Mitapivat for Adult Patients with Erythrocyte Membranopathies (SATISFY): A Framework for Interventional Trials in Rare Anaemias—Pilot Study Protocol. BMJOpen, 14, e083691. https://doi.org/10.1136/bmjopen-2023-083691
[12]
Padeniya, P. and Premawardhena, A. (2024) Obesity, Liver Steatosis and Metabolic Syndrome: The Hidden Enemies in Transfusion‐Dependent Thalassaemia. BritishJournalofHaematology, 205, 28-29. https://doi.org/10.1111/bjh.19532
[13]
Stella, S., Stefano, A., Annalisa, N., et al. (2022) Survival and Late Effects of Hematopoietic Cell Transplantation in Patients with Thalassemia Major. Bone Marrow Transplantation, 57, 1689-1697. https://doi.org/10.1038/s41409-022-01786-4
[14]
Alizadeh, S.R. and Ebrahimzadeh, M.A. (2022) O-substituted Quercetin Derivatives: Structural Classification, Drug Design, Development, and Biological Activities, a Review. JournalofMolecularStructure, 1254, Article ID: 132392. https://doi.org/10.1016/j.molstruc.2022.132392
[15]
Sherief, L.M., Goneim, E., Kamal, N.M., Ibraheim, A., Alsofiani, F. and Alawur, A. (2020) Acute Lymphoblastic Leukemia in a β-Thalassemia Intermedia Child: A Case Report. WorldJournalofClinicalPediatrics, 9, 1-6. https://doi.org/10.5409/wjcp.v9.i1.1
[16]
Molavi, N., Ghaderi, A. and Banafshe, H. (2020) Determination of Thallium in Urine, Blood, and Hair in Illicit Opioid Users in Iran. Human&ExperimentalToxicology, 39, 808-815. https://doi.org/10.1177/0960327120903487
[17]
Mudiyanse, R., Dayasiri, M. and Kulathilake, A. (2019) G409(P) Perceptions of Beta Thalassemia Major Patients and Their Parents about Medical Students’ History Taking Behaviour. Archives of Disease in Childhood, 104, A166. https://doi.org/10.1136/archdischild-2019-rcpch.394
[18]
Domenica, M.C., Antonis, K., et al. (2022) Luspatercept for the Treatment of Anaemia in Non-Transfusion-Dependent β-Thalassaemia (BEYOND): A Phase 2, Randomised, Double-Blind, Multicentre, Placebo-Controlled Trial. TheLancet. Haematology, 9, e733-e744.
[19]
Pahuja, S. and Mandal, P. (2024) Alloimmunization and Autoimmunization among Multitransfused Thalassemia and Sickle Cell Disease Patients. PediatricHematologyOncologyJournal, 9, 200-206. https://doi.org/10.1016/j.phoj.2024.06.002
[20]
Lu, D., Gong, X., Guo, X., Cai, Q., Chen, Y., Zhu, Y., et al. (2024) Gene Editing of the Endogenous Cryptic 3’ Splice Site Corrects the RNA Splicing Defect in the Β654-Thalassemia Mouse Model. HumanGeneTherapy, 35, 825-837. https://doi.org/10.1089/hum.2023.202
[21]
Pistoia, L., Meloni, A., Positano, V., Longo, F., Borsellino, Z., Spasiano, A., et al. (2024) Multiparametric Cardiac Magnetic Resonance Assessment in Sickle Beta Thalassemia. Diagnostics, 14, Article No. 691. https://doi.org/10.3390/diagnostics14070691
[22]
Ali, Z.P., Kumar, M.G., Alina, S., et al. (2023) Calcium Channel Blockers for Preventing Cardiomyopathy Due to Iron Overload in People with Transfusion-Dependent Beta Thalassaemia. TheCochrane Database of Systematic Reviews, 11, CD011626.
[23]
Cannon, E.J., Misialek, J.R., Buckley, L.F., Aboelsaad, I.A.F., Ballantyne, C.M., Leister, J., et al. (2024) Anemia, Iron Deficiency, and Cause-Specific Mortality: The Atherosclerosis Risk in Communities Study. Gerontology, 70, 1023-1032. https://doi.org/10.1159/000539973
